United Therapeutics Corporation Share Price

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 13/07/2024 am IST 5-day change 1st Jan Change
321.4 USD -0.77% Intraday chart for United Therapeutics Corporation +2.17% +46.15%
Sales 2024 * 274.6Cr 23TCr Sales 2025 * 297.73Cr 25TCr Capitalization 1.43TCr 1,19100Cr
Net income 2024 * 118.9Cr 9.93TCr Net income 2025 * 129.7Cr 11TCr EV / Sales 2024 * 4.38 x
Net cash position 2024 * 223.69Cr 19TCr Net cash position 2025 * 336.61Cr 28TCr EV / Sales 2025 * 3.66 x
P/E ratio 2024 *
13 x
P/E ratio 2025 *
11.9 x
Employees 1,168
Yield 2024 *
-
Yield 2025 *
-
Free-Float 58.63%
More Fundamentals * Assessed data
Dynamic Chart
TD Cowen Adjusts Price Target on United Therapeutics to $350 From $270, Maintains Buy Rating MT
Everything's going according to plan Our Logo
Morgan Stanley Downgrades United Therapeutics to Equalweight From Overweight, Adjusts PT to $321 From $310 MT
Analyst recommendations: Albemarle, Levi Strauss & Co, On Semiconductor, Spotify, Costco... Our Logo
United Therapeutics Says Idiopathic Pulmonary Fibrosis Treatment Study Reaches Full Enrollment MT
United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis CI
UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating MT
United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Defensive Index CI
United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Value-Defensive Index CI
United Therapeutics Insider Sold Shares Worth $2,395,035, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $2,285,941, According to a Recent SEC Filing MT
United Therapeutics Corporation Announces Board Changes CI
Tempus, United Therapeutics Launch Collaboration to Use AI to Detect Risk of Pulmonary Hypertension MT
Tempus AI, Inc. Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension CI
United Therapeutics Insider Sold Shares Worth $1,033,984, According to a Recent SEC Filing MT
More news
1 day-0.77%
1 week+2.17%
Current month+0.89%
1 month+11.75%
3 months+38.17%
6 months+46.72%
Current year+46.15%
More quotes
1 week
312.73
Extreme 312.73
330.00
1 month
285.27
Extreme 285.27
330.00
Current year
208.62
Extreme 208.6249
330.00
1 year
208.62
Extreme 208.6249
330.00
3 years
158.38
Extreme 158.38
330.00
5 years
74.31
Extreme 74.31
330.00
10 years
74.31
Extreme 74.31
330.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 26/96/26
President 52 01/11/01
Director of Finance/CFO 56 01/13/01
Members of the board TitleAgeSince
Director/Board Member 76 01/02/01
Chief Executive Officer 69 26/96/26
Director/Board Member 81 01/10/01
More insiders
Date Price Change Volume
12/24/12 321.4 -0.77% 510,091
11/24/11 323.9 -1.63% 596,515
10/24/10 329.2 +2.05% 438,786
09/24/09 322.6 +1.82% 651,847
08/24/08 316.9 +0.74% 351,724

Delayed Quote Nasdaq, July 13, 2024 at 01:30 am IST

More quotes
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
321.4 USD
Average target price
314.5 USD
Spread / Average Target
-2.15%
Consensus